4,528 results match your criteria Contributions to nephrology[Journal]


Protein Energy Wasting and Sarcopenia in Dialysis Patients.

Contrib Nephrol 2018 24;196:243-249. Epub 2018 Jul 24.

As the aging of the population progresses in Japan, the nutritional problems in dialysis patients are being highlighted. Frailty is a clinical concept including body weight loss, muscle weakness, fatigability, decreased walking speed, and decreased physical activity, which means an intermediate concept between healthy subjects and disability subjects, indicating that their activities of daily living are not decreased but they cannot smoothly perform housework or exercise. Morbidity of dialysis patients is known to be high, and mortality of dialysis patients with frailty is 3 times higher. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485729DOI Listing
July 2018
19 Reads

Methods We Currently Use for Home Hemodialysis Management.

Contrib Nephrol 2018 24;196:237-242. Epub 2018 Jul 24.

There are approximately 1,330,000 chronic renal failure patients in Japan, and over 30,000 patients are introduced to dialysis therapy annually. By the end of 2015, there were over 320,000 dialysis patients in Japan. Various groups have been working hard to educate all people involved including the patient, their families, doctors, nurses, and caregivers on three important topics: hemodialysis, peritoneal dialysis, and kidney transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485728DOI Listing
July 2018
24 Reads

Dysnatremia in Renal Failure.

Contrib Nephrol 2018 24;196:229-236. Epub 2018 Jul 24.

Proximal salt reabsorption in the hypertrophied tubules in the early phase of chronic renal failure (CRF) would be diminished according to the inhibited expression of proximal salt-transporting molecules, which may be facilitated by the inhibition of Na-K-ATPase expression. Results from animal models suggest that patients with early-phase CRF would easily develop hyponatremia and, in contrast, patients showing developed CRF would be more likely to show dehydration or hypernatremia. Several large-scale studies of individuals with chronic kidney disease (CKD) revealed that hyponatremia is much more common than hypernatremia in patients with earlier stages of CKD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485727DOI Listing
July 2018
9 Reads

Current Trend of Pediatric Renal Replacement Therapy in Japan.

Authors:
Motoshi Hattori

Contrib Nephrol 2018 24;196:223-228. Epub 2018 Jul 24.

Background: End-stage renal disease (ESRD) in children is considered a rare but serious condition. Information on the epidemiology, demographics, treatment modality at the start of renal replacement therapy (RRT), and mortality of pediatric patients with ESRD is essential for a better understanding of this disease. Additionally, international comparisons of this information on pediatric patients with ESRD may improve outcomes in these children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485726DOI Listing
July 2018
3 Reads

Evidence and Perspectives on the Use of Polymyxin B-Immobilized Fiber Column Hemoperfusion among Critically Ill Patients.

Contrib Nephrol 2018 24;196:215-222. Epub 2018 Jul 24.

Background: Sepsis frequently leads to multiple organ failure due to the uncontrolled amplification and spread of inflammation, even if the infectious source is controlled. Lipopolysaccharide (LPS), a typical pathogen-associated molecular pattern (PAMP), is adsorbed by the polymyxin B-immobilized fiber column (PMX). PMX has been used for decades in Europe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485725DOI Listing
July 2018
14 Reads

Current Practices in Acute Blood Purification Therapy in Japan and Topics for Further Study.

Contrib Nephrol 2018 24;196:209-214. Epub 2018 Jul 24.

Continuous venovenous hemodiafiltration is the modality of choice for acute blood purification therapy at almost all medical institutions in Japan. Nafamostat mesilate, an ultrashort-acting anticoagulant, is widely used for anticoagulation. Due to restrictions imposed by national health insurance, Japanese institutions use an effluent flow rate of 15 mL/kg/h, which is lower than the standard effluent flow rate used in the West. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485724DOI Listing
July 2018
3 Reads

Changes in Treatment with Granulocyte and Monocyte Adsorptive Apheresis from the Past to Future in Patients with Inflammatory Bowel Disease.

Contrib Nephrol 2018 24;196:200-208. Epub 2018 Jul 24.

Background: Idiopathic acute-on-chronic inflammation in the gastrointestinal tract is an etiology of inflammatory bowel disease (IBD). Granulocyte and monocyte adsorptive apheresis (GMA) is a nonpharmacological treatment tool for patients with IBD. Here, we present a review of the positioning and possibilities of GMA for patients with IBD. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/485723
Publisher Site
http://dx.doi.org/10.1159/000485723DOI Listing
July 2018
28 Reads

Our Approaches to Selective Plasma Exchange.

Contrib Nephrol 2018 24;196:194-199. Epub 2018 Jul 24.

Plasma exchange (PE) therapy is the most commonly used treatment in Japan today. The issue with PE is that it removes coagulation factors and other essential molecules during the treatment process. Fresh frozen plasma (FFP) is used to replace the essential molecules which are lost. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485722DOI Listing
July 2018
3 Reads

Apheresis for Kidney Disease.

Contrib Nephrol 2018 24;196:188-193. Epub 2018 Jul 24.

Plasma exchange or double filtration plasmapheresis for rapidly progressive glomerulonephritis, and low-density lipoprotein (LDL) apheresis or leukocytapheresis for nephritic syndrome are two major apheresis therapies for kidney diseases. In addition to these apheresis therapies, plasma exchange for lupus nephritis or LDL apheresis for refractory focal segmental glomerulonephritis is clinically valuable and established. Although several possibilities of apheresis for kidney diseases were speculated in animal experiments or human studies, clinical applications have thus far been limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485721DOI Listing
July 2018
13 Reads

Intensive Hemodialysis: Effects of Treatment Time and Frequency on Time-Averaged Concentrations of Solutes.

Authors:
Michio Mineshima

Contrib Nephrol 2018 24;196:184-187. Epub 2018 Jul 24.

Most of chronic renal disease patients receive 4-h hemodialysis (HD) sessions thrice a week. This is the minimum therapy needed to maintain life. This conventional HD therapy protocol is, however, inadequate to prevent dialysis-related complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485720DOI Listing
July 2018
3 Reads

Home Hemodialysis: Benefits, Risks, and Barriers.

Contrib Nephrol 2018 24;196:178-183. Epub 2018 Jul 24.

Home hemodialysis (HHD) has been available as a modality of renal replacement therapy since the 1960s. HHD allows intensive dialysis such as nocturnal hemodialysis or short daily hemodialysis. Previous studies have shown that patients receiving HHD have an increased survival and better quality of life compared with those receiving in-center conventional HD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485719DOI Listing
July 2018
4 Reads

A Perspective on the Current Status of Home Hemodialysis.

Authors:
Hideki Kawanishi

Contrib Nephrol 2018 24;196:171-177. Epub 2018 Jul 24.

Most hemodialysis (HD) in Japan is based on the central dialysis fluid delivery system (CDDS). With CDDS, there is an improvement in work efficiency, reduction in cost, and a reduction in regional and institutional differences in dialysis conditions. This has resulted in an improvement in the survival rate throughout Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485718DOI Listing
July 2018
3 Reads

Translational Research of Peritoneal Dialysis Solution with Dissolved Molecular Hydrogen.

Contrib Nephrol 2018 24;196:162-170. Epub 2018 Jul 24.

Background: Improved biocompatibility of peritoneal dialysis solution (PDS) is crucial for peritoneal membrane preservation, thereby ensuring long-term peritoneal dialysis (PD) and preventing encapsulating peritoneal sclerosis. We previously reported the protective effect of molecular hydrogen (H2) on mesothelial cells from PDS in nonuremic rats.

Summary: In the present study, we examined the effect of H2-containing PDS (commercially available neutral pH type) regarding the protection of peritoneal tissue in experimental chronic kidney disease rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485717DOI Listing
July 2018
18 Reads

The Role of Non-Tuberculous Mycobacteria in Peritoneal Dialysis-Related Infections: A Literature Review.

Contrib Nephrol 2018 24;196:155-161. Epub 2018 Jul 24.

Background: Peritonitis is one of the most frequent reasons for withdrawal of peritoneal dialysis (PD). Although most cases of PD-related peritonitis can be treated with antibiotics, it is occasionally refractory and culture-negative.

Summary: The causes of refractory PD-related peritonitis include antibiotic-resistant bacteria, fungal peritonitis, biofilm formation in PD catheters, bacterial translocation from the gastrointestinal tract, and encapsulating peritoneal sclerosis. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/485716
Publisher Site
http://dx.doi.org/10.1159/000485716DOI Listing
July 2018
6 Reads

Blood Pressure Control in Peritoneal Dialysis Patients.

Authors:
Munekazu Ryuzaki

Contrib Nephrol 2018 24;196:148-154. Epub 2018 Jul 24.

In the general population, hypertension (HT) is defined as systolic blood pressure (SBP) ≥140 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg. In dialysis patients, the definition is thought to be the same as in the general population. But there is no clear description about the definition of HT for dialysis patients, especially in peritoneal dialysis (PD) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485715DOI Listing
July 2018
4 Reads

Peritoneal Dialysis in Elderly Patients.

Contrib Nephrol 2018 24;196:141-147. Epub 2018 Jul 24.

Background: Dialysis is now often being initiated in older patients. In Japan, patients are around 69 years of age on initiation of dialysis. The total dialysis population undergoing peritoneal dialysis (PD) stands at just 3% in Japan, a much lower proportion than in other industrialized countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485714DOI Listing
July 2018
3 Reads

Effect of Combined Peritoneal Dialysis and Hemodialysis on Health-Related Quality of Life.

Contrib Nephrol 2018 24;196:135-140. Epub 2018 Jul 24.

Background: In Japan, combined peritoneal dialysis (PD) and hemodialysis (HD) therapy is performed widely as an established modality of renal replacement therapy. This combination therapy is indicated for patients who cannot maintain adequate solute clearance using a standard PD prescription, or those who have uremic symptoms or a state of persistent fluid overload. A common treatment schedule for combined PD + HD therapy consists of 5 days of PD and one HD session per week. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485713DOI Listing
July 2018
9 Reads

Current State of Peritoneal Dialysis in Children.

Authors:
Hiroshi Hataya

Contrib Nephrol 2018 24;196:129-134. Epub 2018 Jul 24.

Background: Recent statistics have revealed that the number of patients with preemptive kidney transplant (KTx) has increased to 21.9% between 2006 and 2011. However, factors like body height, lack of kidney source, and severe complications render some patients ineligible for KTx. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485712DOI Listing
July 2018
3 Reads

Current Status of Peritoneal Dialysis in Japan.

Contrib Nephrol 2018 24;196:123-128. Epub 2018 Jul 24.

Background: As an effective renal replacement therapy, peritoneal dialysis (PD) is as important as hemodialysis (HD) and renal transplantation. PD is beneficial for social rehabilitation and home medical care. However, in Japan, there are fewer PD patients than HD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485711DOI Listing
July 2018
3 Reads

Treatment of Hepatitis C Virus Infection in Dialysis Patients.

Authors:
Kan Kikuchi

Contrib Nephrol 2018 24;196:119-122. Epub 2018 Jul 24.

Since 2014, all-oral, interferon (IFN)-free, direct-acting antiviral (DAA) regimens including daclatasvir + asunaprevir dual regimen, ledipasvir/sofosbuvir combination, ombitasvir/paritaprevir/ritonavir combination, elbasvir + grazoprevir dual regimen, and glecaprevir/pibrentasvir combination have been approved for the treatment of hepatitis C. Studies on DAA regimens reported that DAA therapy causes far fewer adverse reactions compared with IFN therapy and exhibits high efficacy in treating hepatitis C virus (HCV) infection in hemodialysis patients, although the ledipasvir/sofosbuvir combination cannot be used for dialysis patients because sofosbuvir is contraindicated for patients with estimated glomerular filtration rate of <30 mL/min/1.73 m2. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/485710
Publisher Site
http://dx.doi.org/10.1159/000485710DOI Listing
July 2018
11 Reads

Intermittent Infusion Hemodiafiltration: The Principle and Its Clinical Application.

Contrib Nephrol 2018 24;196:114-118. Epub 2018 Jul 24.

The present study aimed to propose a new hemodiafiltration (HDF) method (intermittent infusion HDF) that repeats intermittent infusion during hemodialysis to temporarily enhance peripheral circulation and improves solute removal efficiency through (a) correcting blood distribution (increase in effective vascular surface area), (b) stirring body fluids, and (c) promoting solute removal and examining its clinical effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485709DOI Listing
July 2018
3 Reads

Advances and Developments in Vascular Access in Japan.

Authors:
Sachiko Hirotani

Contrib Nephrol 2018 24;196:110-113. Epub 2018 Jul 24.

Background: There are several ways to gain vascular access, including creating an internal shunt, superficialization of the brachial artery, and use of an artificial blood vessel or a catheter. This article describes recent advances and future directions in the field of vascular access in Japan.

Summary: In vascular access techniques using patients' own vessels, such as creating an internal shunt and superficialization of the brachial artery, management and monitoring to maintain healthy conditions is crucial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485708DOI Listing
July 2018
5 Reads

Management of Physical Frailty in Patients Requiring Hemodialysis Therapy.

Contrib Nephrol 2018 24;196:101-109. Epub 2018 Jul 24.

Background: The mean age of people undergoing dialysis therapy has been on the rise because of improved survival in this patient population, as well as the reduced availability of transplants for elderly patients. Aging in Japanese dialysis patients is more rapid than those in the United States and Europe. Frailty is generally considered as an age-related fragile state, and a condition in which the individual is in a vulnerable state at increased risk of adverse health outcomes and/or dying when exposed to a stressor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485707DOI Listing
July 2018
3 Reads

Effects of Levocarnitine on Cardiac Function and Renal Anemia in Hemodialysis Patients.

Authors:
Terumi Higuchi

Contrib Nephrol 2018 24;196:96-100. Epub 2018 Jul 24.

Background: Carnitine deficiency is a common condition in hemodialysis patients. There have been numerous reports on the efficacy of levocarnitine therapy in hemodialysis patients, including different views. Reported effects of levocarnitine are: (1) improvement of renal anemia, (2) improvement of cardiac functions, (3) effects on muscle spasm and asthenia, (4) anti-atherogenic effects, (5) anti-oxidant and anti-inflammatory effects, and (6) inhibitory effects on dialysis hypotension. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485706DOI Listing
July 2018
16 Reads

Current Status and Treatment Strategies of Hemodialysis-Associated Pruritus.

Contrib Nephrol 2018 24;196:88-95. Epub 2018 Jul 24.

Background: Hemodialysis-associated pruritus (HAP) is often treatment-resistant, and is a serious comorbidity that adversely affects prognosis and reduces patient quality of life through sleep disruption and depression.

Summary: HAP can arise from a combination of several causes; accordingly, it is often resistant to treatment. HAP patients need the specific causes of their itching to be identified, with a comprehensive approach to treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485705DOI Listing
July 2018
3 Reads

Ferritin: Diversity and Management of Ferritin Measurement Methods.

Contrib Nephrol 2018 24;196:83-87. Epub 2018 Jul 24.

Background: Serum ferritin is one of the most important and widely used markers of iron metabolism, and is a recommended standard index of iron dynamics in guidelines for renal anemia in many countries. However, serum ferritin measurement has several disadvantages. For example, it is prone to being influenced by underlying disease, and there is considerable systematic bias among different methods of measurement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485704DOI Listing
July 2018
6 Reads

Total Renal Care Approach for Patients with End-Stage Renal Disease.

Contrib Nephrol 2018 24;196:78-82. Epub 2018 Jul 24.

Background: Advances in dialysis medicine have enabled end-stage renal disease (ESRD) patients to live longer. ESRD patients and their family members experience the illness in everyday life, and patients are required to manage their own disease to live longer. Psychological flexibility benefits a person and leads to healthier outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485703DOI Listing
July 2018
3 Reads

Pathogenesis and Management of Vascular Calcification in Patients with End-Stage Renal Disease.

Contrib Nephrol 2018 24;196:71-77. Epub 2018 Jul 24.

Vascular calcification is common in patients with end-stage renal disease (ESRD). In addition to traditional cardiovascular risk factors, ESRD patients also have a number of nontraditional cardiovascular risk factors that may play an important role in the pathogenesis of vascular calcification. The transformation of vascular smooth muscle cells into osteoblast-like cells may be a key element in the pathogenesis of vascular calcification in the presence of calcium and phosphate deposition due to abnormal bone metabolism and impaired renal excretion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485702DOI Listing
July 2018
3 Reads

Does Combined Therapy with Peritoneal Dialysis and Hemodialysis Improve Prognosis?

Authors:
Yukio Maruyama

Contrib Nephrol 2018 24;196:64-70. Epub 2018 Jul 24.

Background: Peritoneal dialysis (PD) is recommended as first-line renal replacement therapy for end-stage renal disease. Combined therapy with PD and hemodialysis (HD) is an option for patients on PD with inadequate dialysis and/or fluid overload that has rapidly gained popularity in Japan.

Summary: The clinical benefits of combined therapy have been recognized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485701DOI Listing
July 2018
15 Reads

Magnesium in Hemodialysis Patients: A New Understanding of the Old Problem.

Contrib Nephrol 2018 24;196:58-63. Epub 2018 Jul 24.

Background: Despite the prognostic significance of mineral and bone disorders in patients undergoing hemodialysis, very few studies have focused on magnesium metabolism in this population. Nephrologists have paid much attention to hypermagnesemia, which is sometimes caused by magnesium administration, but the clinical implication of low magnesium has been largely overlooked. Recently, several cohort studies have reported that lower serum magnesium levels are associated with an increased risk of all-cause and cardiovascular mortality among hemodialysis patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485700DOI Listing
July 2018
19 Reads

Importance of Physiological Erythropoiesis in the Treatment of Chronic Kidney Disease-Associated Anemia.

Contrib Nephrol 2018 24;196:52-57. Epub 2018 Jul 24.

Recent large clinical trials have reported that despite the maintenance of target hemoglobin (Hb) levels, higher doses of erythropoiesis-stimulating agents (ESAs) and/or iron preparations are significantly associated with higher risks of adverse events and death in maintenance hemodialysis (MHD) patients. Higher doses of ESAs have been demonstrated to result in a higher risk for cardiovascular disease due to elevated blood pressure or increased thrombogenicity. In addition, a high dose of iron might enhance inflammatory responses to infection and impair the phagocytic function of neutrophils. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485697DOI Listing
July 2018
3 Reads

Intravenous Maxacalcitol Therapy Correlates with Serum Fibroblast Growth Factor 23 Levels in Hemodialysis Patients Independent of Serum Phosphate or Calcium Levels.

Contrib Nephrol 2018 24;196:44-51. Epub 2018 Jul 24.

Fibroblast growth factor 23 (FGF23) is a regulator of phosphate and vitamin D homeostasis that carries out primary bone- and mineral-related physiological functions to increase renal phosphate excretion and reduce 1α-hydroxylation of 25-hydroxyvitamin D. In a negative endocrine feedback loop, 1,25-dihydroxyvitamin D also stimulates FGF23 secretion. Previous studies have assessed the correlation between vitamin D receptor activator therapy and FGF23 concentrations, and to our knowledge, none has assessed the correlation between intravenous (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485696DOI Listing
July 2018
5 Reads

Targets and Therapeutics for Glycemic Control in Diabetes Patients on Hemodialysis.

Contrib Nephrol 2018 24;196:37-43. Epub 2018 Jul 24.

Background: For diabetes patients without nephropathy, glycemic control is important to reduce the risk or delay the progression of diabetes complications, including nephropathy. In diabetes patients on hemodialysis, good glycemic control is necessary to improve prognosis. Many factors influence the blood glucose level of diabetes patients on hemodialysis, such as factors associated with end-stage kidney disease and factors related to hemodialysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485695DOI Listing
July 2018
3 Reads

Brain Atrophy and Cognitive Impairment in Chronic Kidney Disease.

Contrib Nephrol 2018 24;196:27-36. Epub 2018 Jul 24.

Background: There is an increasing prevalence of dementia associated with population aging, and anti-dementia measures have now become of increasing importance in Japan. Chronic kidney disease (CKD) is a risk factor for cognitive impairment.

Summary: We previously demonstrated that hemodialysis patients have a higher prevalence of brain atrophy, even at younger age, than the general population, and also demonstrated the association between frontal lobe atrophy and frequency of rapid decline in blood pressure during the hemodialysis session. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485694DOI Listing
July 2018
10 Reads

Asymptomatic Cerebrovascular Disease in Dialysis Patients.

Contrib Nephrol 2018 24;196:22-26. Epub 2018 Jul 24.

Cerebrovascular disease is a major cause of death in dialysis patients, who have a much higher incidence of stroke compared to the normal population. Recent studies have shown that asymptomatic cerebral small-vessel disease, including silent brain infarction (SBI), white matter hyperintensities (WMHs), and cerebral microbleeds (CMBs), is related to the future onset of stroke. Cerebral small-vessel disease is caused by microvascular damage to the small penetrating arteries of the middle cerebral artery including arteriolosclerosis, fibrinoid necrosis, and lipohyalinosis attributed to advanced age, hypertension, etc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485692DOI Listing
July 2018
7 Reads

Strategy for Prevention of Left Ventricular Remodeling in Predialysis and Dialysis Patients.

Contrib Nephrol 2018 24;196:13-21. Epub 2018 Jul 24.

Background: Currently, left ventricular (LV) hypertrophy and dysfunction are considered the strongest predictors of cardiovascular mortality in chronic kidney disease (CKD) patients. We investigated the factors associated with elevated LV mass index (LVMI) using echocardiography and assessed the strategies used to treat CKD (stages 1-5D) patients.

Summary: In study 1, we prospectively determined correlations among biochemical values, physical specimens, and LVMI using echocardiography in hemodialysis (HD) and peritoneal dialysis (PD) patients (stage 5D). Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/485691
Publisher Site
http://dx.doi.org/10.1159/000485691DOI Listing
July 2018
20 Reads

Current Perspectives on Sudden Cardiac Death in Hemodialysis Patients.

Contrib Nephrol 2018 24;196:5-12. Epub 2018 Jul 24.

Background: Recent lines of evidence suggest that, as in other countries, sudden cardiac death (SCD) is more common in the Japanese dialysis clinical setting than we previously thought.

Summary: Three specific important findings may underlie the increased incidence of SCD in dialysis patients. Even after successful coronary revascularization, hemodialysis (HD) patients continue to have a higher incidence of SCD than the general population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485690DOI Listing
July 2018
4 Reads

Eosinophilic Inflammation in Peritoneal Fibrosis Patients Undergoing Peritoneal Dialysis.

Contrib Nephrol 2018 24;196:1-4. Epub 2018 Jul 24.

Background: Renal replacement therapy is vital for patients with chronic renal failure. Each type of renal replacement therapy has its own characteristics, and patients select it according on their living environment or conception of quality of life. Under the recent medical environment in Japan, economic burden of dialysis is another concern. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000485689DOI Listing
July 2018
13 Reads

Preliminaries.

Authors:

Contrib Nephrol 2018 7;195:I-X. Epub 2018 May 7.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486928DOI Listing
May 2018
3 Reads

Direct Effects of Immunomodulatory Agents on Podocytes in Immune-Mediated Glomerular Diseases.

Contrib Nephrol 2018 7;195:131-142. Epub 2018 May 7.

Amelioration of podocyte injury, which can lead to podocyte detachment, is the target of therapeutic intervention in glomerular diseases. Since podocytes are terminally differentiated cells with little or no proliferative ability, their loss results in permanent glomerular dysfunction. In immune-mediated glomerular diseases, a variety of immunomodulatory agents are used to maintain podocytes by systemic immunosuppression, which indirectly ameliorates podocyte injury by interrupting the input of immunological stress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486943DOI Listing
May 2018
4 Reads

Use of Beta-Blockers on Maintenance Dialysis Patients and Ischemic Cerebral and Cardiovascular Deaths: An Examination Using Propensity Score.

Contrib Nephrol 2018 7;195:120-130. Epub 2018 May 7.

Beta-blockers are frequently used in dialysis patients because of their cardioprotective properties. However, the effect of beta-blockers on reducing dialysis mortality has not been sufficiently examined to date. Thus, we sought to examine the effects on cardiovascular prognosis of beta-blockers using our outpatient dialysis database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486942DOI Listing
May 2018
2 Reads

Socioeconomics of Administering Rituximab for Nephrotic Syndrome.

Contrib Nephrol 2018 7;195:110-119. Epub 2018 May 7.

Nephrotic syndrome is a type of intractable disease caused by a disorder in the kidneys, which produces swelling. Although some patients show rapid improvement and recover completely with conventional treatment, many others experience frequent recurrence (frequently relapsing nephrotic syndrome) while some remain dependent on the same high dose of steroids they were initially prescribed at the start of treatment (steroid-dependent nephrotic syndrome). In the latter cases, side effects of prolonged steroid use are a major issue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486941DOI Listing
May 2018
9 Reads
1.534 Impact Factor

Role of Frailty on Outcomes of Dialysis Patients.

Contrib Nephrol 2018 7;195:102-109. Epub 2018 May 7.

Frailty is a clinical state in which there is an increase in the individual's vulnerability to developing increased dependency and/or mortality when exposed to a stressor. Since the mean age of dialysis patients is increasing worldwide, frailty has recently come to be considered one of the risk factors for mortality in the older dialysis population. The prevalence of frailty among dialysis patients has ranged from 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486940DOI Listing
May 2018
4 Reads

Treatment of Posttransplantation Anemia.

Contrib Nephrol 2018 7;195:92-101. Epub 2018 May 7.

Kidney transplantation represents a renal replacement therapy for end-stage renal failure, with outcomes improving from year to year. With the improved survival prognosis, treatment of complications of chronic kidney disease after transplantation is becoming increasingly important. In particular, posttransplantation anemia (PTA) is often protracted, which could be related to a variety of factors, including the renal function status, graft rejection episodes, and infectious causes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486939DOI Listing
May 2018
5 Reads
1.530 Impact Factor

Clinical Impact of Left Ventricular Diastolic Dysfunction in Chronic Kidney Disease.

Contrib Nephrol 2018 7;195:81-91. Epub 2018 May 7.

Left ventricular diastolic dysfunction (LVDD) frequently occurs in chronic kidney disease (CKD) and is associated with heart failure and higher mortality. LVDD is observed in patients with early stages of CKD and is associated with cardiovascular events, in patients undergoing incident hemodialysis in the absence of systolic function. The pathogenesis of CKD includes abnormal ventricular filling in diastole and a higher LV filling pressure (LVFP) because of LV hypertrophy (LVH), in addition to myocardial interstitial fibrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486938DOI Listing
May 2018
3 Reads

Cell Sheet Engineering and Kidney Diseases.

Contrib Nephrol 2018 7;195:74-80. Epub 2018 May 7.

Treatment using the cell sheet technology has been applied to various organs, including the cornea, heart, esophagus, periodontium, cartilage, middle ear, and lungs. It has been shown that the therapeutic efficacy of cell sheet transplantation involves 2 aspects, supplementation of cells and provision of cytokines to the affected organ. In addition, cell sheet transplantation also promotes repair of damage through the paracrine effects of cytokines derived from the transplanted cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486937DOI Listing
May 2018
4 Reads

Renal Anemia and Iron Metabolism.

Contrib Nephrol 2018 7;195:62-73. Epub 2018 May 7.

Normal iron metabolism is essential for effective hemoglobin (Hb) production in the management of renal anemia. Considering that studies regarding the optimal Hb levels predated the creation of the iron management indices found in the treatment guidelines for hemodialysis (HD) patients, an increase in the Hb levels caused by intravenous iron supplementation has been used as an iron management index. However, no consideration was given to iron metabolism or the long-term safety of intravenous iron supplementation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486936DOI Listing
May 2018
2 Reads

Association between Increases in Normalized Protein Catabolic Rate and Increases in Creatinine Generation Rate in Dialysis Patients.

Contrib Nephrol 2018 7;195:51-61. Epub 2018 May 7.

The older dialysis population is growing, and malnutrition and wasting syndrome are great concerns in this population. The management of these syndromes includes appropriate nutritional intake and physical activity. However, whether management in the form of an increase in protein intake has a beneficial effect on muscle mass has not been demonstrated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486934DOI Listing
May 2018
7 Reads

Recent Advances in Treatment Strategies for Lupus Nephritis.

Contrib Nephrol 2018 7;195:42-50. Epub 2018 May 7.

Systemic lupus erythematosus (SLE) is an autoimmune chronic inflammatory disease that affects multiple organs and tissues. Lupus nephritis (LN) is a serious complication of SLE, which occurs at a high rate. Conventional treatment strategies of LN have been widely accepted by two concepts such as induction therapy and maintenance therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486933DOI Listing
May 2018
3 Reads

New Insights into Cystic Kidney Diseases.

Contrib Nephrol 2018 7;195:31-41. Epub 2018 May 7.

Hereditary cystic kidney diseases are considered as "ciliopathies" caused by abnormalities of the "primary cilia" situated on the tubules. As a result of dysplasia and dysfunction of cilia, formation of cysts occurs at various stages of life. Although occurring at a low incidence, hereditary cystic kidney diseases that develop from the fetal stage to childhood are diverse and are often associated with systemic disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000486932DOI Listing
May 2018
3 Reads